Company: STAA
Filing Date: 2025-09-16
Form Type: DEFA14A
Source: 0001193125-25-204402
Chunk: 0

Company: STAAR SURGICAL CO
Filing Date: 2025-09-16
Form: DEFA14A
Chunk 0
---
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box:

| ☐ | Preliminary Proxy Statement |

| ☐ | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |

| ☐ | Definitive Proxy Statement |

| ☒ | Definitive Additional Materials |

| ☐ | Soliciting Material under § 240.14a-12 |

STAAR SURGICAL COMPANY (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box):

| ☒ | No fee required. |

| ☐ | Fee paid previously with preliminary materials. |

| ☐ | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 0-11. |

Dear Fellow Stockholders, On August 5, 2025, we announced that STAAR Surgical Company entered into a definitive merger agreement to be acquired by Alcon for $28.00 per share in cash. STAAR will hold a virtual Special Meeting of Stockholders on October 23 at 8:30 a.m. (Pacific Time) to ask for your vote to adopt the merger agreement. The STAAR Board of Directors unanimously determined that the proposed merger with Alcon is in the best interests of STAAR and its stockholders and strongly recommends that you vote “FOR” the merger proposal, as described in the accompanying proxy statement. $28.00 per share is a compelling premium on multiple measures:

| ~51%                               
 Premium to closing stock price day 
 prior to announcement              |     | ~59%           
 Premium        
 to 90-day VWAP |     | Significantly Higher                      
 Premium                                   
 compared to the 26% median for comparable 
 MedTech transactions                      |     | 47%                                        
 Premium                                    
 to median sell-side price targets prior to 
 merger announcement                        |

We believe the value provided by the Alcon merger exceeds what STAAR could achieve on a standalone basis in the foreseeable future, particularly given STAAR’s lower growth rate and the resulting impact on its valuation, and the